Gossamer bio announces first quarter 2025 financial results and provides business update, including closure of new patient screening in phase 3 prosera study

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced its financial results for the first quarter ended march 31, 2025, and announced the closure of new patient screening for the ongoing registrational phase 3 prosera study.
GOSS Ratings Summary
GOSS Quant Ranking